Sorry, you need to enable JavaScript to visit this website.
  1. Home
  2. Our Science
  3. Clinical Trials
  4. Plain Language Study Results Summaries

Plain Language Study Results Summaries

What Are Plain Language Study Results Summaries?

Plain Language Study Results Summaries are descriptions in everyday language of the design and results of clinical studies. These summaries, also called plain language summaries, simple summaries, and trial results summaries, are intended to make clinical results understandable and accessible to patients, healthcare providers, caregivers, researchers, and a general audience.

Please use the search function below to find Plain Language Study Results Summaries for Pfizer-sponsored global clinical trials.

Filter Results

Refine your search results by using the dropdown filters below. Click “reset” to return to the full list of available studies.

Uno studio di ARRY-371797 (PF-07265803) per il trattamento dei pazienti con cardiomiopatia dilatativa sintomatica dovuta alla mutazione del gene della Lamina A/C (REALM-DCM)
Category & Conditions: Cardiovasular Diseases and Conditions
Study Phase : 3
Medicine: PF-07265803
Language: Italian
ViewDownloadPrint
Estudio de ARRY-371797 (PF-07265803) en pacientes con miocardiopatía dilatada sintomática debida a una mutación del gen de lamina A/C (REALM-DCM)
Category & Conditions: Cardiovasular Diseases and Conditions
Study Phase : 3
Medicine: PF-07265803
Language: Spanish
ViewDownloadPrint
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaccine Candidate BNT162b2 in Immunocompromised Participants
Category & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
Eine Studie zur Bewertung der Sicherheit, Verträglichkeit und Immunogenität des Impfstoffkandidaten BNT162b2 bei immunsupprimierten Teilnehmern
Category & Conditions: Vaccine-related Conditions
Study Phase : 2
Medicine: PF-07302048 (BNT162)
Language: German
ViewDownloadPrint
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
Category & Conditions: Coronavirus Disease (COVID-19)
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
Category & Conditions: Coronavirus Disease (COVID-19)
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
A Study to Learn If a Booster Dose of BNT162b2 Was Safe and Effective in Healthy Children and Adults
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
A Study to Learn If a Booster Dose of BNT162b2 Was Safe and Effective in Healthy Children and Adults
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
A Study of BNT162b2 COVID-19 Vaccine Given as a Booster Shot in Healthy Young People 12 to 17 Years Old Who Had Already Received BNT162b2 COVID-19 Vaccine Before
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
Eine Studie zur Untersuchung der Sicherheit einer Auffrischungsdosis von BNT162b2 bei gesunden Kindern und Erwachsenen, die zuvor BNT162b2 erhalten hatten
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: German
ViewDownloadPrint
A Study of the BNT162b2 COVID-19 Vaccine Given at the Same Time as a Flu Vaccine in Adults
Category & Conditions: Coronavirus Disease (COVID-19)
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint
A Study of BNT162b2 COVID-19 Vaccine Given as a Booster Dose in Healthy Adults Aged 60 Years and Older in Israel who had Already Received BNT162b2 COVID-19 Vaccine Before
Category & Conditions: Vaccine-related Conditions
Study Phase : 3
Medicine: PF-07302048 (BNT162)
Language: English
ViewDownloadPrint